What is the most appropriate first‑line preventive medication for chronic migraine in adults?

Best Preventive Medication for Chronic Migraine

For chronic migraine in adults, topiramate is the recommended first-line preventive medication due to its proven efficacy in randomized controlled trials, favorable cost-effectiveness profile, and established safety record. 1

Evidence-Based First-Line Options

The most recent high-quality guideline evidence from Nature Reviews Neurology (2021) identifies three medications with proven effectiveness specifically for chronic migraine 1:

• Topiramate - Designated as the drug of first choice due to substantially lower cost while maintaining proven efficacy 1
• OnabotulinumtoxinA - FDA-approved specifically for chronic migraine prophylaxis 1
• CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) - Proven beneficial but typically reserved for patients who have failed 2-3 other preventive medications due to cost and regulatory restrictions 1

Critical Distinction: Chronic vs. Episodic Migraine

Important caveat: The 2002 Annals of Internal Medicine guidelines 1 recommend propranolol, timolol, amitriptyline, divalproex sodium, and sodium valproate as first-line agents, but these recommendations apply to episodic migraine prevention. The 2021 Nature Reviews Neurology guideline explicitly states there is no robust data from randomized controlled trials supporting beta blockers, candesartan, or amitriptyline for chronic migraine prevention, despite their common use in clinical practice 1.

Practical Treatment Algorithm

Step 1: Rule Out Medication Overuse Headache (MOH)

• Assess for acute medication use ≥10 days/month for triptans or ≥15 days/month for simple analgesics 1
• If MOH present, withdraw overused medication before initiating preventive therapy 1

Step 2: Initiate Topiramate

• Start at low dose and titrate slowly to 50-200 mg/day (typical effective range) 1
• Allow 2-3 months for full clinical benefit to manifest 1
• Monitor for adverse effects: cognitive slowing, paresthesias, weight loss, kidney stones 1

Step 3: Consider Patient-Specific Factors for Alternative First-Line Choices

Choose onabotulinumtoxinA if:

• Patient has failed topiramate or cannot tolerate oral medications 1
• Administered using Phase III PREEMPT protocol by trained specialist 1

Choose CGRP monoclonal antibodies if:

• Two or more preventive medications have failed 1
• Patient requires high adherence/persistence (monthly or quarterly injections) 2
• Cost is not prohibitive or insurance coverage secured 1

Comorbidity-Driven Selection

When topiramate is contraindicated or specific comorbidities exist 1:

• Obesity present: Topiramate preferred (associated with weight loss) 1
• Depression or sleep disturbances: Consider amitriptyline despite limited chronic migraine evidence 1
• Anxiety prominent: Avoid topiramate if cognitive effects problematic 1

Dosing and Monitoring Principles

• Start low, go slow: Initiate at lowest dose and titrate gradually 1
• Adequate trial period: Minimum 2-3 months before assessing efficacy 1
• Headache diary: Essential for tracking monthly headache days and treatment response 1
• Avoid acute medication overuse: Limit triptans to <10 days/month during preventive treatment 1

When to Refer to Specialist

Chronic migraine management is challenging and specialist referral is usually necessary 1:

• At diagnosis confirmation
• When first-line treatments fail
• For onabotulinumtoxinA or CGRP antibody administration
• When MOH complicates the clinical picture 1

Common Pitfalls to Avoid

• Premature discontinuation: Clinical benefit requires 2-3 months; many patients discontinue too early 1
• Inadequate dosing: Failure to titrate to effective dose due to minor side effects 1
• Ignoring MOH: Preventive medications are less effective when acute medications are overused 1
• Using episodic migraine evidence for chronic migraine: Beta blockers and amitriptyline lack robust chronic migraine trial data 1

Newer Evidence Considerations

The 2024 VA/DoD guidelines 1 provide strong recommendations for CGRP antibodies (erenumab, fremanezumab, galcanezumab) for both episodic and chronic migraine, with weak recommendations for topiramate and onabotulinumtoxinA for chronic migraine specifically. However, cost-effectiveness analyses consistently show topiramate as the most cost-effective option up to willingness-to-pay thresholds of £50,000 per quality-adjusted life-year 3.